Provence Technologies acquires Synprosis
Strengthens expertise of French company in its core business of therapeutic chemistry
Provence Technologies Group, a specialist fine chemistry research group located in Marseille, France, has purchased Synprosis, a specialist in the chemical synthesis of peptides and proteins for therapeutic use. Synprosis is based in Aix-en-Provence. The financial terms of the agreement were not disclosed.
The deal opens up new development opportunities for the Provence Technologies Group in the area of biologically active pharmaceuticals. Synprosis has a 10-year history of producing active principles in the field of vaccines under development (for malaria, cancer, and allergies, etc.), as well as in other therapeutic areas such as neurogenerative diseases and the treatment of pain. The company was first recognised for its expertise in creating synthetic vaccines for HIV and malaria. The technology developed by Synprosis is said to offer significantly increased peptide production yields with a cost reduction of 30–40%.
Provence Group’s new entity will be called Provepep. Synprosis will be the division that specialises in pharmaceutical-standard production, in keeping with good manufacturing practices. Jean-Pierre Salles, who founded Synprosis, will remain in the Provepep executive management team.
'I am delighted to see the Synprosis business integrated into Provepep. This is a real asset for us, since there are numerous synergies that can be achieved with the skills developed at Provence Technologies Group,' said Salles. 'It will not just ensure the continuity of our business, but also strengthen it.'
Michel Feraud, Chairman and CEO of Provence Technologies Group, said: 'The development of biologically active pharmaceuticals has already been a reality for some years. Synprosis provides technology solutions that restore the standing of small protein production via chemical synthesis, with a higher level of purity at a competitive cost.
'With the new generation of Methylene Blue from our Provepharm subsidiary, we are proving ourselves to be dynamic players in the field of pharmacy through innovation in chemical synthesis. The active peptides sector is enjoying rapid growth and we are counting on Provepep to be an excellent division for the group.'
